More recently, the IL-18/ILC2 axis has also emerged in cancer research, shaping the immune landscape within the tumor microenvironment in CRC, gastric cancer, and CML [16, 31, 39]. This evidence concerns the gene IL18 and chronic myelogenous leukemia, BCR-ABL1 positive.